CR Double-Crane subsidiary gets approval for azilsartan API

China Resources Double-Crane Pharmaceutical (SSE: 600062) announced that its holding subsidiary, Zhejiang Xinsaike Pharmaceutical Co., Ltd., has received a "Chemical API Listing Application Approval Notice" from the National Medical Products Administration for its Azilsartan API. Azilsartan is an angiotensin II receptor blocker (ARB) used to treat hypertension. The company invested approximately RMB 373.24 million in R&D for the API. The API has been registered on the CDE's platform. There are currently 13 companies in China registered to produce Azilsartan API. CR Double-Crane noted that the launch and sales of the API are subject to uncertainties, including regulatory and market factors.